This involved carrying out a randomized double-blind clinical trial to compare the efficacy of buccally absorbed prochlorperazine (BAP) to intravenous prochlorperazine (IVP) for the abortive treatment of migraine headaches.
17 December, 2024
This involved carrying out a randomized double-blind clinical trial to compare the efficacy of buccally absorbed prochlorperazine (BAP) to intravenous prochlorperazine (IVP) for the abortive treatment of migraine headaches.